News
The First Step of CAR-T Commercialization
As a new method of individualized tumor immunotherapy, CAR-T cell therapy has shown great therapeutic potential. However, commercial operation means new challenges. Compared with traditional chemicals, "living" biopharmaceuticals have greater uncertainty, potential problems...
The effect of interleukin on the function of NK cells（IL-1β, IL-12, IL-15, IL-18, IL-21）
Natural killer cells originate from bone marrow lymphoid stem cells and are innate immune effector cells in the body. They are named after their non-specific cytotoxicity. The killing activity of NK cells is not limited by MHC and does not depend on antibodies, hence it is called natural killing activity.
Summary of Protein Factors Involved in Hematopoietic Stem Cell Culture
In recent years, stem cells have become increasingly widely used in clinical applications. However, the proportion and quantity of stemcells in the human body are extremely low, which cannot meet clinical needs.
Overseas Exhibition Preview | T&L Will Participate in SITC 2023 San Diego, USA
The 38th Society for Immunotherapy of Cancer (SITC) Annual Conference will be held from November 1-5 in San Diego, USA.
New Product Launch | Nanoscale Sorting Magnetic Beads Weighing Heavily~
Cell therapy has developed rapidly in recent years in pharmaceutical research and development, and is a new drug development model that has shown great potential in the treatment of diseases such as cancer, infectious diseases, and autoimmune diseases.
Good News | T&L CGT Core Raw Material CD28 Monoclonal Antibody Has Completed FDA DMF Filing
Recently, Beijing T&L Biotechnology Ltd. (referred to as "T&L") successfully obtained the US FDA DMF registration for its CGT core raw material CD28 monoclonal antibody, with DMF registration number 038820.
Good News | T&L Cell Therapy Key Materials Have Been Registered with Fda Dmf, Helping Your Drug Application Process
Recently, Beijing T&L Biotechnology Ltd. (hereinafter referred to as "T&L") received a confirmation letter from the US Food and Drug Administration (hereinafter referred to as "FDA"), stating that the company's key raw materials for cell therapy drugs, CD3 monoclonal antibody, and T cell sorting activation magnetic beads, have officially completed the DMF type II filing with the US FDA.
![[Blockbuster] T&L CGT core raw materials have been re-registered with the US FDA DMF](https://ecdn6-nc.globalso.com/upload/p/1757/image_product/2024-06/news1.jpg)
[Blockbuster] T&L CGT core raw materials have been re-registered with the US FDA DMF
We are pleased to announce that after obtaining DMF registration for CD3 monoclonal antibody and CD3/CD28 sorting activated magnetic beads, T&L's GMP grade products, recombinant human IL-7 protein (Cat. No. GMP-TL506) ...